CA-LEGENDARY-PICTURES
25.8.2022 16:02:11 CEST | Business Wire | Press release
Coming off the global success of 2021’s “Godzilla vs Kong” cameras are now rolling on the latest entry in Warner Bros. Pictures’ and Legendary Pictures’ cinematic Monsterverse. This latest entry follows up the explosive showdown of Godzilla vs. Kong with an all-new cinematic adventure, pitting the almighty Kong and the fearsome Godzilla against a colossal undiscovered threat hidden within our world, challenging their very existence – and our own. The epic new film will delve further into the histories of these Titans, their origins and the mysteries of Skull Island and beyond, while uncovering the mythic battle that helped forge these extraordinary beings and tied them to humankind forever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005274/en/
The film, which recently began principal photography, is again being helmed by director Adam Wingard (“You’re Next” “The Guest”) and stars returning cast members Rebecca Hall (“The Night House” “Resurrection”), Brian Tyree Henry (“Bullet Train” “Atlanta”), and Kaylee Hottle (“Godzilla vs. Kong”), who are now joined by newcomers Dan Stevens (“Gaslit” “Legion” “Beauty and the Beast”), Fala Chen (“Irma Vep” “Shang Chi and the Legend of the Ten Rings”), Alex Ferns (“The Batman” “Wrath of Man” “Chernobyl”) and Rachel House (“Hunt for the Wilderpeople” “Thor: Ragnarok” “Foundation”).
Wingard is directing the currently untitled project from a script by Terry Rossio (“Godzilla vs. Kong” the “Pirates of the Caribbean” series), Jeremy Slater (“Moon Knight”) and Simon Barrett (“You’re Next”). The film is being produced by Mary Parent, Alex Garcia, Eric Mcleod, Brian Rogers, Thomas Tull, and Jon Jashni, with executive producers Josh Grode, Adam Wingard, Jay Ashenfelter, Jen Conroy, Kenji Okuhira and Yoshimitsu Banno.
Once again, Wingard is collaborating with director of photography Ben Seresin (“Godzilla vs. Kong” “World War Z”), production designer Tom Hammock (“Godzilla vs. Kong” “X” “The Guest”), editor Josh Schaeffer (“Godzilla vs. Kong” “Molly’s Game”), and composer Tom Holkenborg (“Godzilla vs. Kong” “Mad Max: Fury Road”), who are now joined by costume designer Emily Seresin (“The Invisible Man” “Top of the Lake”), makeup artist Sabrina Wilson (“Captain Marvel” “The Suicide Squad” “The Book of Bobba Fett”), hairstylist Gloria Pasqua Casny (“The Tomorrow War” “Ford vs Ferrari”), and VFX supervisor Alessandro Ongaro (“The Adam Project” “Ghostbusters: Afterlife”).
The film is being shot on location in Queensland, Australia and is slated for a March 15, 2024, worldwide release from Warner Bros. Pictures except in Japan where it will be distributed by Toho Co., Ltd and in mainland China where it will be distributed by Legendary East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220825005274/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom